Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Transmedics Group Inc (TMDX)

Transmedics Group Inc (TMDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,760,880
  • Shares Outstanding, K 34,532
  • Annual Sales, $ 605,490 K
  • Annual Income, $ 190,290 K
  • EBIT $ 109 M
  • EBITDA $ 136 M
  • 60-Month Beta 2.09
  • Price/Sales 6.45
  • Price/Cash Flow 28.81
  • Price/Book 8.20

Options Overview Details

View History
  • Implied Volatility 76.53% (-1.15%)
  • Historical Volatility 56.28%
  • IV Percentile 72%
  • IV Rank 57.64%
  • IV High 100.33% on 07/17/25
  • IV Low 44.14% on 06/10/25
  • Expected Move (DTE 23) 16.21 (14.31%)
  • Put/Call Vol Ratio 0.48
  • Today's Volume 271
  • Volume Avg (30-Day) 1,249
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 23,132
  • Open Int (30-Day) 23,643
  • Expected Range 97.09 to 129.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.62
  • Number of Estimates 5
  • High Estimate $0.82
  • Low Estimate $0.55
  • Prior Year $0.70
  • Growth Rate Est. (year over year) -11.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
93.08 +20.87%
on 03/30/26
120.91 -6.95%
on 04/17/26
-1.39 (-1.22%)
since 03/20/26
3-Month
93.08 +20.87%
on 03/30/26
151.00 -25.49%
on 03/04/26
-25.58 (-18.52%)
since 01/22/26
52-Week
88.50 +27.13%
on 04/28/25
156.00 -27.88%
on 12/02/25
+21.30 (+23.35%)
since 04/22/25

Most Recent Stories

More News
TransMedics to Report First Quarter 2026 Financial Results on May 5, 2026

ANDOVER, Mass. , April 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 112.50 (+3.30%)
TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results

ANDOVER, Mass. , Feb. 27, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 112.50 (+3.30%)
TransMedics: Q4 Earnings Snapshot

TransMedics: Q4 Earnings Snapshot

TMDX : 112.50 (+3.30%)
TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results

ANDOVER, Mass. , Feb. 24, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 112.50 (+3.30%)
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANDOVER, Mass. , Feb. 20, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 112.50 (+3.30%)
TransMedics to Present at Upcoming March Investor Conferences

ANDOVER, Mass. , Feb. 17, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 112.50 (+3.30%)
TransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

ANDOVER, Mass. , Feb. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 112.50 (+3.30%)
TransMedics Receives Full and Unconditional FDA IDE Approval for Next-Generation OCS Heart ENHANCE Trial

ANDOVER, Mass. , Feb. 9, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 112.50 (+3.30%)
TransMedics Announces New Global Headquarters and Expansion at Assembly Innovation Park in Somerville, Massachusetts

ANDOVER, Mass. , Jan. 12, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a global leader in organ transplant technologies and services, today announced the signing...

TMDX : 112.50 (+3.30%)
TransMedics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

ANDOVER, Mass. , Dec. 30, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 112.50 (+3.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

TransMedics Inc. is a commercial-stage medical technology company. It is engaged in transforming organ transplant therapy for end-stage organ failure patients. The company offers Organ Care System, an integrated, compact, portable preservation technology which addresses unmet need for organs for transplantation....

See More

Key Turning Points

3rd Resistance Point 117.54
2nd Resistance Point 115.67
1st Resistance Point 112.29
Last Price 112.50
1st Support Level 107.04
2nd Support Level 105.17
3rd Support Level 101.79

See More

52-Week High 156.00
Fibonacci 61.8% 130.21
Fibonacci 50% 122.25
Fibonacci 38.2% 114.28
Last Price 112.50
52-Week Low 88.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.